Pitavastatin in cardiometabolic disease: therapeutic profile - Wikidata - wikimedia - TriplyDB

Pitavastatin in cardiometabolic disease: therapeutic profile

Pitavastatin in cardiometabolic disease: therapeutic profile

http://www.wikidata.org/entity/Q21246037

about

Modulation of microRNA Expression in Subjects with Metabolic Syndrome and Decrease of Cholesterol Efflux from Macrophages via microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1 Expression by Statins Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome

P2860

Q28551738-527FCF31-41B1-48B9-8B7D-8B95144A5F16 Q34467988-2501F45B-8774-46A7-BA7D-2E989FA63184 Q34687470-3C48FE3D-C3B2-4BFE-B6AB-D1E29526FDC3 Q35501523-2E5C29A9-7B36-4B4C-A99B-A3224800B658 Q38268344-28FB1029-4162-49FE-AB10-4A623BA097EB Q39038196-9D711681-1E4F-4902-B28A-0749D288B0DF Q41265772-AA4AF118-C3F1-48C3-A501-032D6EC29C7C

P2860

Pitavastatin in cardiometabolic disease: therapeutic profile

http://www.wikidata.org/entity/Q21246037

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pitavastatin in cardiometabolic disease: therapeutic profile

@ast

Pitavastatin in cardiometabolic disease: therapeutic profile

@en

Pitavastatin in cardiometabolic disease: therapeutic profile

@en-gb

Pitavastatin in cardiometabolic disease: therapeutic profile

@nl

type

label

Pitavastatin in cardiometabolic disease: therapeutic profile

@ast

Pitavastatin in cardiometabolic disease: therapeutic profile

@en

Pitavastatin in cardiometabolic disease: therapeutic profile

@en-gb

Pitavastatin in cardiometabolic disease: therapeutic profile

@nl

prefLabel

Pitavastatin in cardiometabolic disease: therapeutic profile

@ast

Pitavastatin in cardiometabolic disease: therapeutic profile

@en

Pitavastatin in cardiometabolic disease: therapeutic profile

@en-gb

Pitavastatin in cardiometabolic disease: therapeutic profile

@nl

P1433

Q21246037-5736C85E-174F-49FA-B344-95DF5AA1950D

P1476

Q21246037-8119F1AA-4123-4234-B7FA-81422CD904E5

P2093

Q21246037-D8D1E221-78D4-4DC8-93B1-9EE3D3F67EB7

P275

Q21246037-C42867C8-04A7-4EB2-A9B1-6C691C878AE5

P2860

Q21246037-0752EEDC-71CA-4C1D-9CF4-1B09B6FF292A

Q21246037-0C0D4B69-CBC9-4F1B-952B-B1EB5851AD87

Q21246037-0D9B1505-0929-4A1D-A943-07771A791301

Q21246037-14425886-036B-444B-A7ED-4A84D786D6F9

Q21246037-165022A6-9BD7-4E77-A5B3-8BFFA11E0F36

Q21246037-19877688-0BF7-48D4-840B-BA9190310FBE

Q21246037-19B32154-9B22-46FF-98B8-0ECB57B3F26E

Q21246037-1D8CD390-A71F-48BB-818D-A9DDA6488EB4

Q21246037-26281DEA-4DD4-46DD-9A97-5C00AE534DD3

Q21246037-2CEF1C61-0C93-48D0-B141-C5FA7B7FFBF5

P2888

Q21246037-0A0C4934-8071-4CBB-AFD0-35D064D52A68

P304

Q21246037-F6453408-16AD-45A0-9342-42D576116BC4

P31

Q21246037-52710EB4-73E9-4434-9555-860F39F47B1E

Q21246037-BF1A00B5-B9AC-4AA3-8C7D-F6C02603BCEE

P3181

Q21246037-7455CCB1-479F-4FEB-A5CB-A25CF361E53B

P356

Q21246037-3CF03556-E24A-44BD-9415-CE45F52E0866

P407

Q21246037-C25C577E-EFC0-4522-808D-851BF871D74C

P433

Q21246037-471E8156-B93E-494F-A2FA-D12EEC092054

P478

Q21246037-C6CF5F82-EC1E-499B-85B2-41D8995B0676

P5008

Q21246037-A152AEC2-AB97-4155-B966-B09F4A9B4A5C

P577

Q21246037-2D453946-461F-4081-AC8F-E5731FB6836B

P6179

Q21246037-2DE40D4D-1803-4939-A3A0-4965B41B08B4

P698

Q21246037-B369D050-84C6-42B1-8930-8FAABEE92AF8

P921

Q21246037-57D58CFF-DC13-45A9-A020-84BE322D97A9

Q21246037-7DEFEEB3-FAA2-4BD0-A2F2-09561BA92816

Q21246037-C2D114DD-812E-449A-BEC2-511F2EAF94AB

Q21246037-CBC4F98F-CE58-4F90-BA66-EABB37579E46

Q21246037-D07FF327-F52F-4C7B-819F-43A1A8158895

Q21246037-D53DCAFD-9E23-4EE0-9726-1CCC2ABEA3A0

P932

Q21246037-F90D6AA2-AE81-4BCF-B5BC-B89C98BB1F59

P3181

P356

1475-2840-12-S1-S2

P1433

Cardiovascular Diabetology

P1476

Pitavastatin in cardiometabolic disease: therapeutic profile

@en

P2093

Luis Masana

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

P2888

1475-2840-12-s1-s2

P304

S2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1902818

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1475-2840-12-S1-S2

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

12 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1031564125

http://www.w3.org/2001/XMLSchema#string

P698

23819752

http://www.w3.org/2001/XMLSchema#string

P921

lipid metabolism disorder

heterocyclic compound

mechanism of action

cardiovascular disease

metabolic syndrome

P932

3668168

http://www.w3.org/2001/XMLSchema#string